BAT Group has acquired a 19.9% equity stake in Organigram, forming a strategic collaboration to enhance cannabis product development focused on CBD.
Target Information
BAT Group (British American Tobacco) has entered into a strategic collaboration agreement with Organigram Inc., a leading Canadian licensed cannabis producer. Organigram, which is a wholly-owned subsidiary of publicly traded Organigram Holdings Inc., specializes in the research and development of adult-use recreational and medical cannabis products, legally available in Canada. This partnership primarily aims to enhance product development activities focused on cannabidiol (CBD), leveraging both companies' expertise in plant-based science.
With a proven track record in consumer-led innovation, Organigram offers high-quality cannabis products that align with current market demands. Through this collaboration, BAT aims to not only enhance its product portfolio but also deepen its understanding of the rapidly evolving cannabis sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The cannabis industry in Canada has experienced significant growth since its legalization for recreational use in 2018. The country has positioned itself as a global leader in cannabis production and regulation, attracting significa
Similar Deals
Clearstone Capital → Brust Beverages
2025
Fondaction, Investissement Québec → Cultures Gen V
2024
Fiducie agricole UPA-Fondaction → Ferme Tournevent
2023
BAT Group
invested in
Organigram Inc.
in 2021
in a Strategic Partnership deal
Disclosed details
Transaction Size: $163M
Equity Value: $163M